XELJANZ (tofacitinib): Important Safety Information from Pfizer Healthcare Ireland as approved by the HPRA

Notice type: 3rd Party Publications

Date: 17/02/2020

 

Problem Or Issue:

Important Safety Information from Pfizer Healthcare Ireland on increased risk of venous thromboembolism and increased risk of serious and fatal infections XELJANZ (tofacitinib)

Important Safety Information - XELJANZ (tofacitinib)

To read more Press Release articles, click here.